3,4-dimethoxyphenylacetonitrile

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1980

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Comparable to acute tox. method. Non-GLP.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1980

Report date:

1980

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

other: BASF Test

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

veratrylcyanid

IUPAC Name:

veratrylcyanid

Constituent 2

Reference substance name:

78/834

IUPAC Name:

78/834

Details on test material:

Veratrylcyanid; no data on purity given in the report

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

- diet: Herilan MRH-Haltung; H. Eggersmann KG

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: 0.5 % aqueous CMC

Doses:

50, 200 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- way of application: intraperitoneal
- form of application: suspension
- formulation in: 0.5% aqueous carboxymethyl cellulose
- fasting before application: 15 - 20 h
- observation period: 14 days
- max. volume applied: 10 mL/kg bw.
- range of concentration: 2.0-0.5 % (g/v)

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 50 - < 200 mg/kg bw

Mortality:

Mortality in male rats after 1 hour/1 day/2 days/7 days/14 days:
- 200 mg/kg bw dose level: 5/5/5/5/5
- 50 mg/kg bw dose level: 0/0/0/0/0


Mortality in female rats after 1 hour/1 day/2 days/7 days/14 days:
- 200 mg/kg bw dose level: 5/5/5/5/5
- 50 mg/kg bw dose level: 1/1/1/1/1

Clinical signs:

- 200 mg/kg bw dose level: dyspnoe, apathy, abnormal position, staggering, atonia, no reflex on pain, convulsion, exsiccosis, poor general state.
- 50 mg/kg bw dose level: dyspnoe, apathy, abnormal position, staggering, tremor, convulsion, exsiccosis, poor general state.

Body weight:

Mean body weight [g] in male rats before application/2-4 days after appl./7 days after appl./13 days after appl.
- 464 mg/kg bw dose level:----
- 316 mg/kg bw dose level: 24/27.6/30.6/34.2


Mean body weight [g] in female rats before application/2-4 days after appl./7 days after appl./13 days after appl.
- 464 mg/kg bw dose level:----
- 316 mg/kg bw dose level: 24/25/27.5/28.3

Any other information on results incl. tables

Groups of 5 male and 5 female NMRI mice were given a single intraperitoneal 
injection of the test substance at dose levels of 50 and 200 mg/kg bw. For 
application, the test substance was suspended in a 0.5% aqueous preparation of 
carboxymethylcellulose; the suspensions were injected at 10 ml/kg bw. After 
dosing, the animals were observed for 14 days. One low dose female and all high 
dose animals died within one hour after dosing. Signs of toxicity were observed 
at both dose levels and included dyspnea, apathy, anomal position, staggering, 
atony, loss of pain reflex, narcotic-like state, tremor, spastic gait, rolling 
fitm, tonic convulsion, clonic convulsion, exsiccosis and poor general state. 
Body weight gains of the survivors were within the expected range. Post-mortem
 examination of the decedents and survivors revealed no pathological findings

Applicant's summary and conclusion

Conclusions:

Since the test substance was administrated intraperitonealy, no classification is warranted according to Regulation (EU) No. 1272/2008 and Directive 67/548/EEC, respectively.